Featured Research & Media

Selected scientific highlights

JAMA

Precision immunotherapy to improve sepsis outcomes.

The ImmunoSep project represents an important milestone in personalized immunotherapy for sepsis. Its successful evaluation by the European Commission and the publication of the ImmunoSep randomized clinical trial in JAMA highlight the project’s scientific achievements and its contribution to precision medicine.

Research highlights

Read the JAMA publication

European Commission evaluation announcement

CCR Down Under 2025, December 9th & 10th, Melbourne:

The Best Critical Care Trials in the World

Professor Evangelos J. Giamarellos-Bourboulis  presented the ImmunoSep trial, one of the top clinical trials in the world marking a milestone for Greece’s presence in international medicine.

THE LANCET

Respiratory Medicine

FEATURED CLINICAL TRAIL · 2024
ACCESS Trial: Advancing the Treatment of Community-Acquired Pneumonia

The ACCESS randomized clinical trial, published in The Lancet Respiratory Medicine, investigated clarithromycin as an adjunctive treatment for community-acquired pneumonia. The study contributes to understanding inflammation-targeted approaches and highlights the role of clinical research in managing severe infections.

Related publications

 ACCESS Randomized Clinical Trial 

The Lancet Respiratory Medicine

 Molecular Pathways Driving Clarithromycin Benefit

EBioMedicine · 2026

Conferences & Scientific Events

Lisbon, Portugal | October 10–14, 2026

ESICM LIVES 2026

Scientific contributions on personalized immunomodulation, precision immunotherapy and the EMBRACE trial.

View conference highlights

24–27 SEPTEMBER 2026 · ATHENS

EMBRACE THE FUTURE

Celebrating 20 years of the Hellenic Sepsis Study Group and international scientific collaboration.

View conference highlights

Our success stories

Regulatory Impact
SAVE-MORE · EMA & FDA

Regulatory milestone for anakinra in COVID-19 treatment.

Discover the milestone →

Scientific Innovation
Precision immunotherapy

Advancing personalized immunotherapy through clinical research.

Discover the milestone →

Greek Guidelines for Sepsis
Definitions and Principles of Sepsis Management

Explore the latest Greek guidelines and published bulletins on the definition, diagnosis, and management of sepsis, providing evidence-based recommendations to support clinical practice.

View the Guidelines →

Loading...

Latest publications

Annals of Intensive Care, Volume 16, 2026

Innate immune response in COVID-19 pneumonia during the pandemic: a prospective cohort study

14 October 2026

EBioMedicine 2026 Apr 3

Molecular pathways driving clarithromycin benefit in community-acquired pneumonia analysis of the ACCESS randomised trial

6 April 2026

Cell Reports Medicine, January 2, 2026

A randomized controlled trial of precision bezlotoxumab treatment for Clostridioides difficile infection

3 January 2026

SHOCK, Vol. 65

Blood biomarker and Raman analysis of leukocytes in the multicenter INTELLIGENCE trials: at the Intensive Care Unit (INTELLIGENCE-1) and the Emergency Department (INTELLIGENCE-2)

2 January 2026

The Lancet Regional Health - Europe 2026

Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled phase IIa trial

2 January 2026

JAMA 2026 Mar 3

Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial

14 December 2025

Metabolism Open, Volume 28, 2025

Hydrogen sulfide to modulate Glycated hemoglobin and gut microbiome in type 2 diabetes mellitus

23 October 2025

Front. Cell. Infect. Microbiol. 15

An NGS-assisted diagnostic workflow for culture-independent detection of bloodstream pathogens and prediction of antimicrobial resistances in sepsis

1 September 2025

Our Founding History

At the dawn of the financial crisis in Greece, a group of 14 researchers and clinicians realized the need to struggle to maintain a high level of research and education for sepsis and systemic inflammation that are the main disorders leading to death in our world. This group inaugurated in July 2010 the Hellenic Institute for the Study of Sepsis (HISS), a nonprofit, non-commercial organization.

Find out how it all started

The last eleven years, the Executive Board and the General Assembly are proud to present a very vivid workload summarized as a) continuing support to the investigators of the Hellenic Sepsis Study Group; b) continuing education in sepsis by the organization of thirteen national and international workshops and conferences and by the publications of Greek guidelines in sepsis; c) fifteen completed clinical studies and ten ongoing clinical studies in Greece; four of the clinical trials are international with other European Countries; d) support of PhD theses in sepsis; and e) 72 original publications in international peer-reviewed medical journals.
HISS is pioneer in personalized medicine and is presenting as major achievement the design, conduct, analysis and publication of the double-blind, pivotal trial SAVE-MORE for the successful management of moderate to severe COVID-19 pneumonia with anakinra guided by the biomarker suPAR. This trial was conducted in 37 study sites in Greece and Italy; 606 patients were enrolled and the study received advice from COVID-ETF of the European Medicines Agency.

Our Publications Library

Our Publications Library

Discover all our pioneering work in various research topics
Studies

Studies

Get connected to our network of databases and helpful sites
Conferences

Conferences

Learn more about our gatherings
Validation strategy

Validation strategy

Our know-how and precision planning has lead to authorization from renowned organizations
Facilities

Facilities

Learn more about our infrastructure
0+
scientific papers
0+
citations
0+
visits
0+
centers worldwide
0+
thesis

Linkedin news